Skip to main content

JADPRO Live 2024 Main banner

Icon Legend

ICONS KEY

CE Credit Available

CE Credit Available

Pharmacology Credit Available

Pharmacology Credit Available

Poster Activities

Poster Activities

Surgical Oncology

Surgical Oncology

Browse by Title

Browse by Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

L
Lunch Activity/Non-CE Accredited Satellite Symposium: A Coordinated Care Team Approach to the Management of Patients Taking Jakafi for Chronic Graft-Versus-Host Disease
Incyte Corporation
Seating is available on a first-come, first-served basis.
Lunch Activity/Non-CE Accredited Satellite Symposium: A First-Line Treatment Option for Adults with Symptomatic Anemia Due To Lower-Risk MDS
Bristol Myers Squibb
Seating is available on a first-come, first-served basis.
Lunch Activity/Non-CE Accredited Satellite Symposium: Review of evidence-based data for an antibody-drug conjugate in combination with a PD-1 inhibitor for 1L la/mUC
Astellas Pharma Inc. and Pfizer Oncology Inc.
Lunch Activity/Non-CE Accredited Satellite Symposium: Subcutaneous Administration: An Alternative Route of Administration in Oncology Treatment
Bristol Myers Squibb
Lunch Activity/Non-CE Accredited Satellite Symposium: The AEGEAN Regimen: Neoadjuvant IMFINZI® (durvalumab) + Platinum-Containing Chemotherapy Then Adjuvant IMFINZI for Resectable (Tumors ≥4 cm and/or Node Positive) NSCLC With No Known EGFR Mutations or ALK Rearrangements
AstraZeneca
Lunch Activity/Non-CE Accredited Satellite Symposium: The Facts on the Combined Power of RYBREVANT® + LAZCLUZE for the First-Line Treatment of EGFR+ Locally Advanced or mNSCLC
Johnson & Johnson
Seating is available on a first-come, first-served basis.
Lunch Activity/Non-CE Accredited Satellite Symposium: Thrombotic Risk and Symptom Assessment in Patients With Polycythemia Vera | A Collaborative Approach to Identifying When to Intervene With Jakafi® (ruxolitinib)
Incyte Corporation
Lunch Activity/Non-CE Accredited Satellite Symposium: Treatment of Adults With Certain BRAF–Mutated Metastatic Melanoma, Colorectal, and Non-Small Cell Lung Cancers
Pfizer, Inc.
Seating is available on a first-come, first-served basis.
Lunch Activity/Non-CE Accredited Satellite Symposium: A Consideration for Patients With Relapsed or Refractory Multiple Myeloma
Johnson & Johnson